Advanced Enzyme Technologies Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Biotechnology
Key metrics
Price as of 2026-07-20
Stock price
₹319.05
Market cap
3,570 Cr
Stock P/E
20.6
P/B
2.12
Dividend yield
1.7%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 147 Cr | 158 Cr | 161 Cr | 158 Cr | 155 Cr | 146 Cr | 169 Cr | 167 Cr | 186 Cr | 185 Cr | 172 Cr | 203 Cr |
| Operating expenses (approx.) | 103 Cr | 107 Cr | 107 Cr | 108 Cr | 103 Cr | 104 Cr | 114 Cr | 113 Cr | 129 Cr | 124 Cr | 111 Cr | 133 Cr |
| EBITDA | 44 Cr | 51 Cr | 54 Cr | 50 Cr | 51 Cr | 42 Cr | 55 Cr | 54 Cr | 56 Cr | 60 Cr | 61 Cr | 71 Cr |
| OPM % | 29.9% | 32.5% | 33.4% | 31.5% | 33.1% | 29.0% | 32.7% | 32.5% | 30.4% | 32.5% | 35.2% | 34.7% |
| Other income | 7 Cr | 6 Cr | 14 Cr | 9 Cr | 7 Cr | 10 Cr | 8 Cr | 9 Cr | 9 Cr | 10 Cr | 8 Cr | 7 Cr |
| Interest | 0.65 Cr | 0.75 Cr | 0.68 Cr | 0.85 Cr | 0.87 Cr | 0.93 Cr | 0.94 Cr | 0.81 Cr | 0.76 Cr | 0.72 Cr | 0.57 Cr | 0.57 Cr |
| Depreciation | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 9 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr | 10 Cr |
| Profit before tax | 41 Cr | 48 Cr | 59 Cr | 40 Cr | 49 Cr | 42 Cr | 53 Cr | 43 Cr | 55 Cr | 60 Cr | 58 Cr | 60 Cr |
| Tax % | 29.0% | 26.6% | 27.8% | 24.6% | 28.1% | 20.9% | 26.7% | 38.5% | 26.3% | 24.9% | 25.9% | 24.3% |
| Net profit | 29 Cr | 35 Cr | 43 Cr | 30 Cr | 35 Cr | 33 Cr | 39 Cr | 27 Cr | 40 Cr | 45 Cr | 43 Cr | 45 Cr |
| EPS (₹) | ₹2.58 | ₹3.08 | ₹3.74 | ₹2.53 | ₹3.05 | ₹2.94 | ₹3.36 | ₹2.37 | ₹3.57 | ₹3.87 | ₹3.80 | ₹3.84 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 420 Cr | 444 Cr | 502 Cr | 529 Cr | 541 Cr | 624 Cr | 637 Cr | 746 Cr | Sign in for TTM |
| Operating expenses (approx.) | 233 Cr | 236 Cr | 261 Cr | 322 Cr | 388 Cr | 435 Cr | 409 Cr | 470 Cr | Sign in for TTM |
| EBITDA | 187 Cr | 208 Cr | 240 Cr | 208 Cr | 152 Cr | 189 Cr | 227 Cr | 275 Cr | Sign in for TTM |
| OPM % | 44.6% | 46.8% | 47.9% | 39.3% | 28.2% | 30.3% | 35.7% | 36.9% | Sign in for TTM |
| Other income | 5 Cr | 6 Cr | 9 Cr | 6 Cr | 25 Cr | 37 Cr | 33 Cr | 35 Cr | Sign in for TTM |
| Interest | 4 Cr | 3 Cr | 2 Cr | 2 Cr | 2 Cr | 3 Cr | 4 Cr | 3 Cr | Sign in for TTM |
| Depreciation | 21 Cr | 26 Cr | 28 Cr | 35 Cr | 35 Cr | 35 Cr | 37 Cr | 40 Cr | Sign in for TTM |
| Profit before tax | 162 Cr | 179 Cr | 210 Cr | 171 Cr | 140 Cr | 188 Cr | 187 Cr | 233 Cr | Sign in for TTM |
| Tax % | 28.4% | 25.7% | 28.0% | 27.6% | 26.0% | 27.1% | 28.5% | 25.3% | Sign in for TTM |
| Net profit | 116 Cr | 133 Cr | 151 Cr | 124 Cr | 104 Cr | 137 Cr | 134 Cr | 174 Cr | Sign in for TTM |
| EPS (₹) | ₹9.95 | ₹11.58 | ₹13.09 | ₹10.70 | ₹9.45 | ₹11.92 | ₹11.72 | ₹15.08 | Sign in for TTM |
| Dividend payout % | — | — | — | 0.0% | 12.1% | 41.4% | 44.1% | 34.4% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr | 22 Cr |
| Reserves | 657 Cr | 817 Cr | 948 Cr | 1,066 Cr | 1,213 Cr | 1,302 Cr | 1,398 Cr | 1,610 Cr |
| Borrowings | — | — | — | — | 13 Cr | 25 Cr | 12 Cr | 13 Cr |
| Other liabilities | — | — | — | — | 124 Cr | 139 Cr | 140 Cr | 143 Cr |
| Total liabilities | — | — | — | — | 1,422 Cr | 1,535 Cr | 1,621 Cr | 1,839 Cr |
| Fixed assets (net) | — | — | — | — | 273 Cr | 277 Cr | 293 Cr | 276 Cr |
| CWIP | — | — | — | — | 16 Cr | 31 Cr | 22 Cr | 51 Cr |
| Investments | — | — | — | — | 360 Cr | 403 Cr | 480 Cr | 584 Cr |
| Other assets | — | — | — | — | 722 Cr | 810 Cr | 880 Cr | 1,044 Cr |
| Total assets | — | — | — | — | 1,422 Cr | 1,535 Cr | 1,621 Cr | 1,839 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | 124 Cr | 140 Cr | 141 Cr | 142 Cr | 157 Cr |
| Cash from investing | — | — | — | -26 Cr | -298 Cr | -65 Cr | -89 Cr | -74 Cr |
| Cash from financing | — | — | — | -27 Cr | -26 Cr | -59 Cr | -73 Cr | -70 Cr |
| Net cash flow | — | — | — | 75 Cr | -171 Cr | 17 Cr | -20 Cr | 15 Cr |
| Free cash flow (OCF − Capex) | — | — | — | 95 Cr | 102 Cr | 99 Cr | 109 Cr | 105 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 24.4% | 21.7% | 21.8% | 15.9% | 9.0% | 11.0% | 12.9% | 13.9% |
| ROE % | 16.4% | 15.4% | 15.1% | 11.0% | 8.2% | 9.7% | 8.9% | 10.0% |
| Debtor days | — | — | — | — | 68 | 58 | — | — |
| Inventory days | — | — | — | — | 354 | 349 | 354 | 332 |
| Days payable | — | — | — | — | 69 | 37 | — | — |
| Cash conversion cycle | — | — | — | — | 352 | 369 | 354 | 332 |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.0084 | 0.0075 |
| Current ratio | — | — | — | — | 9.31 | 7.61 | 9.09 | 9.78 |
| Net debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | -0.55 | -0.47 | -0.36 | -0.35 |
Compare with peers
Loading peers…